Related references
Note: Only part of the references are listed.Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
B. Homet Moreno et al.
BRITISH JOURNAL OF CANCER (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
EGFR T790M resistance mutation in non small-cell lung carcinoma
Marc G. Denis et al.
CLINICA CHIMICA ACTA (2015)
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
Valsamo K. Anagnostou et al.
CLINICAL CANCER RESEARCH (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunotherapy for lung cancer: for whom the bell tolls?
Pedro Madureira et al.
TUMOR BIOLOGY (2015)
Nivolumab in NSCLC: latest evidence and clinical potential
Raghav Sundar et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Nivolumab for the treatment of cancer
Anasuya Gunturi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
OX40-and CD27-Mediated Costimulation Synergizes with Anti-PD-L1 Blockade by Forcing Exhausted CD8+ T Cells To Exit Quiescence
Sarah L. Buchan et al.
JOURNAL OF IMMUNOLOGY (2015)
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
Jing Lu et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
Miguel F. Sanmamed et al.
CANCER JOURNAL (2014)
B7-H1/PD-1 Blockade Therapy in Non-Small Cell Lung Cancer Current Status and Future Direction
Scott Gettinger et al.
CANCER JOURNAL (2014)
Immune Checkpoint Inhibitors in NSCLC
Douglas B. Johnson et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2014)
Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4
James Badger Wing et al.
IMMUNITY (2014)
Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
S.N. Gettinger et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
Puey Ling Chia et al.
CLINICAL EPIDEMIOLOGY (2014)
Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy
Christopher J. Nirschl et al.
CLINICAL CANCER RESEARCH (2013)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Mario Sznol et al.
CLINICAL CANCER RESEARCH (2013)
Tumor-Infiltrating Regulatory T Cells Inhibit Endogenous Cytotoxic T Cell Responses to Lung Adenocarcinoma
Anusha-Preethi Ganesan et al.
JOURNAL OF IMMUNOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
Zahra Hanaizi et al.
EUROPEAN JOURNAL OF CANCER (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Ipilimumab: its potential in non-small cell lung cancer
Pascale Tomasini et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
Alison M. Paterson et al.
JOURNAL OF IMMUNOLOGY (2011)
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
L. Crino et al.
ANNALS OF ONCOLOGY (2010)
Targeting the Immune System in Non-Small-Cell Lung Cancer: Bridging the Gap Between Promising Concept and Therapeutic Reality
Ronan J. Kelly et al.
CLINICAL LUNG CANCER (2010)
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
O. Akbari et al.
MUCOSAL IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab
Antoni Ribas
SEMINARS IN ONCOLOGY (2010)
The New Lung Cancer Staging System
Frank C. Detterbeck et al.
CHEST (2009)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma
Koichiro Matsumoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen et al.
CLINICAL CANCER RESEARCH (2008)
Molecular origins of cancer: Lung cancer
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature
Jonathan A. Hill et al.
IMMUNITY (2007)
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
Antoni Ribas et al.
ONCOLOGIST (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
KA Sheppard et al.
FEBS LETTERS (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism
BR Blazar et al.
JOURNAL OF IMMUNOLOGY (2003)
Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling
CE Rudd et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A
E Chuang et al.
IMMUNITY (2000)
Share Paper
